Bought some GFRP today...
...GFR Pharmaceuticals filed its 10-K today. 2004 EPS came in at $.38 vs $.19, sales were $5.9M vs $5M, shares outstanding is about 1M, float is about 500K. Alot of this year's EPS came from currency translation; operating EPS were about $.16.
Q4 was strong, with revenues of $2M vs $1.4M and operating EPS of $.08 vs a loss of $.07.
Upcoming (Q1) comparison is easy, with last year's revenues totaling $1.2M and a loss of $.10.
Book value is about $1.40/share and revenue per share is over $5.
The spread is obnoxious currently $.55 bid, $1.05 ask...
When it comes to P/Es, 7 is the new 14...